An Overview of the Hematological Picture with Antithyroid Therapy in Graves'Disease

Хематолошка слика код Гравесове болести

  • Aksanur Gökçe medıcal doctor
DOI: https://doi.org/10.5937/afmnai39-36192
Keywords: Graves’ disease, neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio, platelet-lymphocyte ratio, mean platelet volüme

Abstract


Aim: Graves' disease (GD) is an autoimmune thyroid disease that is the most common cause of hyperthyroidism. Peripheral blood cell parameters such as neutrophils, lymphocytes, and platelets, play a role in inflammation control. Several studies have proven that neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR) are indicators of chronic subclinical inflammation in various diseases. In our study, we aimed to review the peripheral blood picture by evaluating these parameters before and after antithyroid treatment in patients with Graves' disease.

Materials and Methods: A total of 120 patients (93 female, 27 male) between the ages of 18-65 were included. Demographic data, hemogram and biochemical data of the patients were recorded retrospectively at the time of diagnosis and after euthyroidism was achieved with medical treatment.

Results: During the treatment, there was an increase in hemoglobin, lymphocytes, neutrophils and red cell distribution width, while a decrease in monocytes was observed. There was no significant difference between white blood cell, platelet and mean platelet volume. In addition, while there was no difference between NLR (p=0.8) and TLR (p=0.078) after euthyroid state, a significant difference was found in favor of a decrease in MLR (p= 0.006).

Conclusion: Changes in hematopoiesis are relatively common in patients with newly diagnosed GD, and initiation of antithyroid therapy leads to improvement in these parameters. Although NLR, MLR and PLR are accepted as new, non-invasive markers in clinical evaluation, in our study only a significant decrease in MLR levels was observed after euthyroidism was achieved with antithyroid treatment.

References

1. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves' disease.  Autoimmun Rev. 2014;13(4-5):398-402.


 


2. Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves' disease:  Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris). 2018; pii: S0003-4266(18)31245-9.


 



  1. Salvi M, et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000;143:197–202.


 



  1. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003; 24: 802–835.


 



  1. Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92:2157–2162


 


6. Lee YH, Song GG. Neutrophil-to-lymphocyte ratio, mean platelet volume and platelet-to-lymphocyte ratio in Behçet's disease and their correlation with disease activity: A meta-analysis. Int J Rheum Dis. 2018;11.


 


7. Shi L, Qin X, Wang H, et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017; 8(12):18792-18801. 8. Prasek K, Płazińska MT, Królicki L. Diagnosis and treatment of Graves' disease with particular emphasis on appropriate techniques in nuclear medicine. General state of knowledge. Nucl Med Rev Cent East Eur. 2015;18(2):110-6.


 



  1. Ford HC, Carter JM. The haematology of hyperthyroidism: abnormalities of erythrocytes, leucocytes, thrombocytes and haemostasis. Postgrad Med J. 1988;64(756):735-42. doi: 10.1136/pgmj.64.756.735. PMID: 3076660; PMCID: PMC2429012.

  2. Hambsch K, Herrmann F, Fischer H, Langpeter D, Mäller P, Sorger D. Blutbildveränderungen bei Hyperthyreose [Changes in the blood picture in hyperthyroidism]. Z Gesamte Inn Med. 1989;44(10):300-6. German. PMID: 2503948.

  3. Artemniak-Wojtowicz D, Witkowska-Sędek E, Borowiec A, Pyrżak B. Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy. Cent Eur J Immunol. 2019;44(2):132-137. doi: 10.5114/ceji.2019.87063. Epub 2019 Jul 30. PMID: 31530982; PMCID: PMC6745550.

  4. Reddy J, Brownlie BE, Heaton DC, Hamer JW, Turner JG. The peripheral blood picture in thyrotoxicosis. N Z Med J. 1981;93(679):143-5. PMID: 6940035.

  5. Geetha JP, Srikrishna R. Role of red blood cell distribution width (rdw) in thyroid dysfunction. Int J Biol Med Res. 2012;3:1476–1478

  6. Kawa MP, Grymula K, Paczkowska E, et al. Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. Eur J Endocrinol. 2010;162(2):295-305. doi: 10.1530/EJE-09-0875. Epub 2009 Nov 10. PMID: 19903799.

  7. Dorgalaleh A, Mahmoodi M, Varmaghani B, et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Ped Hematol Oncol. 2013;3(2):73-7. Epub 2013 Apr 22. PMID: 24575274; PMCID: PMC3915449.

  8. Kurata Y, Nishioeda Y, Tsubakio T, Kitani T. Thrombocytopenia in Graves' disease: effect of T3 on platelet kinetics. Acta Haematol. 1980;63(4):185-90. doi: 10.1159/000207396. PMID: 6771949.

  9. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-17. doi: 10.1056/NEJMra042972. PMID: 15745981.

  10. Peng Y, Qi Y, Huang F, et al. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave's disease. Oncotarget. 2016;7(48):78680-78687. doi: 10.18632/oncotarget.12019. PMID: 27637079; PMCID: PMC5346669.


 



  1. Dağdeviren M, Akkan T, Yapar D, et al. Can neutrophil/lymphocyte ratio be used as an indicator of inflammation in patients with hyperthyroidism? J Med Biochem. 2020;39(1):7-12. doi: 10.2478/jomb-2019-0004. PMID: 32549771; PMCID: PMC7282227.

  2. 20. Szydełko J, Litwińczuk M, Szydełko M, Matyjaszek-Matuszek B. Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Relation to Clinical Parameters and Smoking Status in Patients with Graves' Orbitopathy-Novel Insight into Old Tests. J Clin Med. 2020;9(10):3111. doi: 10.3390/jcm9103111. PMID: 32993174; PMCID: PMC7600876.


 



  1. Rydzewska M, Jaromin M, Pasierowska IE, Stożek K, Bossowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018;11:2. doi: 10.1186/s13044-018-0046-9. PMID: 29449887; PMCID: PMC5812228.

  2. Turan E. Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves' disease. Bratisl Lek Listy. 2019;120(6):476-480. doi: 10.4149/BLL_2019_076. PMID: 31223030


 



  1. Celik T. Neutrophil-to-lymphocyte ratio in thyroid ophthalmopathy. Bratisl Lek Listy. 2017;118(8):495-498. doi: 10.4149/BLL_2017_095. PMID: 29050489.


 



  1. Schmohl J, Vogel W, Gallwitz B, Möhle R. Thrombozytopenie bei Morbus Basedow [Thrombocytopenia in Graves' disease]. Dtsch Med Wochenschr. 2012;137(20):1056. German. doi: 10.1055/s-0032-1305007. Epub 2012 May 23. PMID: 22622480.

  2. Ushiki T, Masuko M, Nikkuni K, et al. Successful remission of Evans syndrome associated with Graves' disease by using propylthiouracil monotherapy. Intern Med. 2011;50(6):621-5. doi: 10.2169/internalmedicine.50.4319. Epub 2011 Mar 15. PMID: 21422690.

  3. Chhabra S, Tenorio G. Thrombotic thrombocytopenic purpura precipitated by thyrotoxicosis. J Clin Apher. 2012;27(5):265-6. doi: 10.1002/jca.21210. Epub 2012 May 30. PMID: 22644892.

  4. 27. Wenisch C, Myskiw D, Gessl A, Graninger W. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab. 1995;80(7):2122-6. doi: 10.1210/jcem.80.7.7541802. PMID: 7541802.

  5. Dasgupta R, Atri A, Jebasingh F, et al. Platelet-lymphocyte ratıo (plr) as a novel surrogate marker to dıfferentıate thyrotoxıc patıents wıth graves' dısease (gd) from sub-acute thyroıdıtıs (sat): a cross-sectıonal study from south ındıa. Endocr Pract. 2020. doi: 10.4158/EP-2020-0086. Epub ahead of print. PMID: 32407659.

  6. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 1980;303(6):302-7. doi: 10.1056/NEJM198008073030603. PMID: 6247656.


 

Published
2025/12/21
Issue
Vol. 39 No. 4 (2022): Acta facultatis medicae Naissensis
Section
Originalni rad / Original article